Cannabidivarin

Cannabidivarin
Clinical data
ATC code	none;
Identifiers
	IUPAC name 2-((1S,6S)-3-methyl-6-(prop-1-en-2-yl); cyclohex-2-enyl)-5-propylbenzene-1,3-diol;
CAS Number	24274-48-4 ;
PubChem CID	11601669;
DrugBank	DB14050 ;
ChemSpider	21106275 ;
UNII	I198VBV98I;
KEGG	C20217;
ChEMBL	ChEMBL2387742;
CompTox Dashboard (EPA)	DTXSID70893921 ;
ECHA InfoCard	100.236.933
Chemical and physical data
Formula	C19H26O2
Molar mass	286.415 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C=C(C)[C@H]2CCC(\C)=C/[C@@H]2c1c(O)cc(CCC)cc1O;
	InChI InChI=1S/C19H26O2/c1-5-6-14-10-17(20)19(18(21)11-14)16-9-13(4)7-8-15(16)12(2)3/h9-11,15-16,20-21H,2,5-8H2,1,3-4H3/t15-,16+/m1/s1 ; Key:REOZWEGFPHTFEI-CVEARBPZSA-N ;
	(what is this?) (verify)

Cannabidivarin (CBDV, GWP42006) is a non-intoxicating psychoactive cannabinoid found in Cannabis. It is a homolog (chemistry) of cannabidiol (CBD), with the side-chain shortened by two methylene bridges (CH₂ units).

Although cannabidivarin (CBDV) is usually a minor constituent of the cannabinoid profile, enhanced levels of CBDV have been reported in feral populations of C. indica ( = C. sativa ssp. indica var. kafiristanica) from northwest India, and in hashish from Nepal.^[1]^[2]^[3]

CBDV demonstrated anticonvulsant in rodent models in a single published study.^[4] It was identified for the first time in 1969 by Vollner et al.^[5]

Similarly to CBD, it has seven double bond isomers and 30 stereoisomers (see: Cannabidiol#Isomerism). It is not scheduled by Convention on Psychotropic Substances. It is being actively developed by GW Pharmaceuticals (as GWP42006)^[6] because of a demonstrated neurochemical pathway for previously observed anti-epileptic and anti-convulsive action.^[7] GW has begun several Phase-2 trials for adult epilepsy,^[8] for childhood epilepsy and for Prader-Willi Syndrome.^[9]^[10]

References

^ Turner CE, Cheng PC, Lewis GS, Russell MH, Sharma GK (1979). "Constituents of Cannabis sativa XV: Botanical and chemical profile of Indian variants". Planta Medica. 37 (3): 217–25. doi:10.1055/s-0028-1097331. S2CID 83483599.
^ Hillig KW, Mahlberg PG (June 2004). "A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae)". American Journal of Botany. 91 (6): 966–975. doi:10.3732/ajb.91.6.966. PMID 21653452.
^ Merkus FW (August 1971). "Cannabivarin and tetrahydrocannabivarin, two new constituents of hashish". Nature. 232 (5312): 579–580. Bibcode:1971Natur.232..579M. doi:10.1038/232579a0. PMID 4937510. S2CID 4219797.
^ Hill AJ, Mercier MS, Hill TD, Glyn SE, Jones NA, Yamasaki Y, et al. (December 2012). "Cannabidivarin is anticonvulsant in mouse and rat". British Journal of Pharmacology. 167 (8): 1629–1642. doi:10.1111/j.1476-5381.2012.02207.x. PMC 3525866. PMID 22970845.
^ Vollner L, Bieniek D, Korte F (January 1969). "[Hashish. XX. Cannabidivarin, a new hashish constituent]". Tetrahedron Letters. 10 (3): 145–147. doi:10.1016/S0040-4039(01)87494-3. PMID 5778489.
^ "GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP42006". GW Pharmaceuticals. 21 February 2018. Retrieved 28 May 2019.
^ Amada N, Yamasaki Y, Williams CM, Whalley BJ (2013). "Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression". PeerJ. 1: e214. doi:10.7717/peerj.214. PMC 3840466. PMID 24282673.
^ "GW Pharmaceuticals Initiates Phase 2 Clinical Study of Cannabidivarin (CBDV) in Epilepsy" (Press release). GW Pharmaceuticals. May 6, 2015. Retrieved November 10, 2015.
^ "GW Pharma Press release". Archived from the original on 2015-11-21.
^ "NSW advice to practitioners on Medical Cannabis trials" (PDF). Archived from the original (PDF) on 2015-11-21.

External links

Erowid Compounds found in Cannabis sativa
Cannabidivarin

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.

[1] Turner CE, Cheng PC, Lewis GS, Russell MH, Sharma GK (1979). "Constituents of Cannabis sativa XV: Botanical and chemical profile of Indian variants". Planta Medica. 37 (3): 217–25. doi:10.1055/s-0028-1097331. S2CID 83483599.

[HilligMahlberg-2] Hillig KW, Mahlberg PG (June 2004). "A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae)". American Journal of Botany. 91 (6): 966–975. doi:10.3732/ajb.91.6.966. PMID 21653452.

[3] Merkus FW (August 1971). "Cannabivarin and tetrahydrocannabivarin, two new constituents of hashish". Nature. 232 (5312): 579–580. Bibcode:1971Natur.232..579M. doi:10.1038/232579a0. PMID 4937510. S2CID 4219797.

[4] Hill AJ, Mercier MS, Hill TD, Glyn SE, Jones NA, Yamasaki Y, et al. (December 2012). "Cannabidivarin is anticonvulsant in mouse and rat". British Journal of Pharmacology. 167 (8): 1629–1642. doi:10.1111/j.1476-5381.2012.02207.x. PMC 3525866. PMID 22970845.

[5] Vollner L, Bieniek D, Korte F (January 1969). "[Hashish. XX. Cannabidivarin, a new hashish constituent]". Tetrahedron Letters. 10 (3): 145–147. doi:10.1016/S0040-4039(01)87494-3. PMID 5778489.

[GWPharm18-6] "GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP42006". GW Pharmaceuticals. 21 February 2018. Retrieved 28 May 2019.

[7] Amada N, Yamasaki Y, Williams CM, Whalley BJ (2013). "Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression". PeerJ. 1: e214. doi:10.7717/peerj.214. PMC 3840466. PMID 24282673.

[8] "GW Pharmaceuticals Initiates Phase 2 Clinical Study of Cannabidivarin (CBDV) in Epilepsy" (Press release). GW Pharmaceuticals. May 6, 2015. Retrieved November 10, 2015.

[9] "GW Pharma Press release". Archived from the original on 2015-11-21.

[10] "NSW advice to practitioners on Medical Cannabis trials" (PDF). Archived from the original (PDF) on 2015-11-21.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

See also

References

External links